Information  X 
Enter a valid email address

GlaxoSmithKline PLC (GSK)

  Print      Mail a friend       Annual reports

Friday 04 August, 2017

GlaxoSmithKline PLC

Base prospectus re £15bn EMTN programme

RNS Number : 1341N
GlaxoSmithKline PLC
04 August 2017
 

Publication of Base Prospectus

 

The following base prospectus dated 3 August 2017 has been approved by the UK Listing Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital K.K. £15,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the National Storage Mechanism and will shortly be available for inspection at and can be downloaded from:

www.morningstar.co.uk/uk/NSM  

For further information, please contact:

GlaxoSmithKline plc

980 Great West Road

Brentford

Middlesex

TW8 9GS

United Kingdom

 

Enquiries:

UK Media enquiries:

David Mawdsley

Simon Steel

(020) 8047 5564

(020) 8047 3763

 

European Analyst/Investor enquiries:

James Dodwell

Craig Haffey

 (020) 8047 2406

 (020) 8047 6313

 

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base prospectus whether or not you are part of the intended addressees of the information contained therein. 

Your right to access this service is conditional upon complying with the above requirements.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
PDIUGUUURUPMURC

a d v e r t i s e m e n t